Pretty cheap for a biotech with an approved product. Of course, cheap is not always a good value. But here, I think the risk/reward ratio is favorable, and Roche is a good, if maybe a little overbearing parent. Not hearing great things about management, but quality leadership is very rare in biotech. Here we at least have solid science. GLTALs.